We’d love to hear your feedback on this activity. It helps us to continually improve our products.
We were delighted to have the honour of speaking to Jeffrey Cohen (Cleveland Clinic, Cleveland, OH, USA), the president of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). He shared positive findings and expert insight from the phase 3 INROADS study, which investigated the safety and efficacy of amantadine extended release capsules […]
Patrick Vermersch (University of Lille and CHU Lille, Lille, France) shares promising findings and expert insight from the phase 3 study of masitinib for the treatment of progressive multiple sclerosis (ClinicalTrials.gov identifier: NCT01433497). This discussion was based on his MSVirtual2020 presentation: FC04.01 Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: Results […]
Valued editorial board member Jeffrey Cummings (University of Nevada, Las Vegas [UNLV], and Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) shares exciting insights from the session he co-chaired at AAIC20 entitled ‘Microbiome in Alzheimer’s Disease: Pathogenesis and Treatment Implications’. Questions 1. Could you give us a brief overview of the role of […]
Professor Emeritus of Addiction Medicine, Hannu Alho (University of Helsinki, Finland) discusses the need for effective treatment options to manage alcohol use disorder, focusing on odansetron as a newly emerging possibility. Ondansetron is a specific 5HT3-receptor antagonist, which blocks 5HT3 receptors in the gastrointestinal tract and central nervous system, and has been used since the […]
Hans-Christoph Diener (Medical Faculty of the University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany), talks to us around the highlights of his recently published co-authored review article entitled: Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke, freely available to access here. Questions 1. What is […]
Christoph U Correll (Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA) shares his expert insights on the rationale for combined therapy with olanzapine and samidorphan for the management of patients with schizophrenia. He also provides an overview of the key efficacy and safety findings of the recent phase III ENLIGHTEN-2 study, which evaluated weight […]
Christoph U Correll (Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA) shares his expert insights on the rationale for combined therapy with olanzapine and samidorphan for the management of patients with schizophrenia. He also provides an overview of the key efficacy and safety findings of the recent phase III ENLIGHTEN-2 study, which evaluated weight gain […]
Get the latest clinical insights from touchNEUROLOGY